[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1986

Intraoperative Probe-Directed Immunodetection Using a Monoclonal Antibody

Author Affiliations

From the Division of Surgical Oncology, the Department of Surgery (Drs O'Dwyer, McCabe, Farrar, and Martin, Mr Rousseau, and Ms Mojzisik), the Department of Pathology (Drs Tuttle and Barth), the Department of Electrical Engineering (Dr Thurston), and the Department of Nuclear Medicine (Messers Hinkle and Rousseau and Dr Olsen), Ohio State University College of Medicine, Columbus.

Arch Surg. 1986;121(12):1391-1394. doi:10.1001/archsurg.1986.01400120037005
Abstract

• To assess monoclonal antibody (MAb) 17-1A and its F(ab')2 fragment in intraoperative radioimmunodetection and to evaluate further the clinical usefulness of a hand-held gamma-detecting probe (GDP), we injected radiolabeled monoclonal antibody 17-1A three to six days preoperatively or its F(ab')2 fragment two to three days preoperatively into 18 patients with colorectal cancer. Intraoperative GDP counts with tumor-tissue ratios of 1.5:1 or greater were obtained from 15 (75%) of 20 tumor sites, with ratios averaging 2.3:1 for fragments and 3.4:1 for whole antibody. The GDP counts contributed to intraoperative decision making in three patients, either by localization of tumor not identified by inspection or palpation or by mapping margins of resection with histologic confirmation of a local/regional recurrence. These preliminary data demonstrate that probe-directed, intraoperative radioimmunodetection can assist the surgeon in detecting subclinical tumor deposits and thus better evaluate the extent of primary or recurrent colorectal cancers intraoperatively.

(Arch Surg 1986;121:1391-1394)

×